"Essential modelling & bioinformatics to advance preclinical decision making"

 
Tumour Models London, 3 Dec 2019
Workshop

18. Essential modelling & bioinformatics to advance preclinical decision making. Tumour models (Hanson Wade), DoubleTree by Hilton - Tower of London, London (12/2019) PDF (Parts 1 & 3), PDF (Part 2)

Objectives

• Recognise the importance of translation

• Xenograft model: Characterisation, translation, evaluation

• Syngeneic model: Characterisation, translation

• Patient population: Characterisation, translation

Lecture 1. Clinical translation of xenograft models (Tao)

The importance of translation

• Regulatory approval requirements

• Success rate in oncology drug discovery & development projects

• 3 pillars & 5Rs

Clinical translation of xenograft models

• NCI: Mouse MTD efficacy does not predict clinical efficacy

• Chemo: Mouse MTD AUC and clinical AUC => clinical fate

• Chemo: Qualify A2780 (ovarian) xenograft model with PK/PD modelling

• Chemo & Targeted therapy: Preclinical efficacy => Clinical efficacy (ORR)

Lecture 2. Using bioinformatics to aid clinical translation to models (John Prime)

Range of omics data types

• Data complexity in clinical/patient samples 

• Value of integrating the right models to the right granularity of patient data

 

Example I:

• Small molecules/targeted therapy – Selecting the right PDX models to match a patient subset

• Challenges, caveats and pitfall

Tools and omics data sources (i) 

 

Biologics – Cancer Immunotherapy

• The challenges of modelling the immune system in cancer

• Response: Tissue of origin not accurate predictor 

• Cancer immunotherapy – Requires a holistic data paradigm

 

Example II:

• Biologics - Immunotherapy

• Further challenges, caveats and pitfalls

Tools and omics data sources (ii) – Cancer Immunotherapy

Group exercise 1 (John Prime)

Characterise a patient population for a new CI target and match it to in vitro/in vivo models

Lecture 3. Clinical translation of syngeneic models (Tao)

Clinical translation of syngeneic models

• Adaptive immunity to tumours

• Resistance mechanisms to immunotherapy

Case study: Modelling efficacy of RT/αPD-L1 combination treatment in CT26 syngeneic tumour model

Group exercise 2 (Tao)

What are the questions to consider when prospectively translating syngeneic model results into the clinics? 

Licence

The slides (containing the aPD-L1 - RT PK/PD model in P59~64) are made available as part of The Open Project (https://github.com/theopenproject):

GNU General Public Licence v3.0

https://github.com/TheOpenProject/TOM/blob/master/LICENSE

• Permissions of this strong copyleft licence are conditioned on making available complete source code of licensed works

and modifications, which include larger works using a licensed work, under the same licence. Copyright and licence

notices must be preserved. Contributors provide an express grant of patent rights.

Company registration no. 09698685

Registered in England and Wales.

14 Tytherington Park Road, Macclesfield, Cheshire, UK  SK10 2EL 

Beyond Consulting Ltd

+44-7853 073 731